
Egym is also a unicorn; however, formally the fitness company is now a subsidiary of the newly founded American parent company Playlist. As a result, Egym is no longer considered an independent Munich unicorn.

Founded in 2019, Munich-based biotech startup Tubulis develops innovative antibody-drug conjugates (ADCs) designed to deliver cancer therapies directly to tumour cells. In April 2026, US pharmaceutical group Gilead Sciences announced the acquisition of Tubulis for up to five billion dollars. The Munich site will continue operating as a research centre.
























